Your browser doesn't support javascript.
loading
MYC Deregulation and PTEN Loss Model Tumor and Stromal Heterogeneity of Aggressive Triple-Negative Breast Cancer.
Doha, Zinab O; Wang, Xiaoyan; Calistri, Nicholas L; Eng, Jennifer; Daniel, Colin J; Ternes, Luke; Kim, Eun Na; Pelz, Carl; Munks, Michael; Betts, Courtney; Kwon, Sunjong; Bucher, Elmar; Li, Xi; Waugh, Trent; Tatarova, Zuzana; Blumberg, Dylan; Ko, Aaron; Kirchberger, Nell; Pietenpol, Jennifer A; Sanders, Melinda E; Langer, Ellen M; Dai, Mu-Shui; Mills, Gordon; Chin, Koei; Chang, Young Hwan; Coussens, Lisa M; Gray, Joe W; Heiser, Laura M; Sears, Rosalie C.
Afiliação
  • Doha ZO; Department of Molecular and Medical Genetics, Oregon Health & Science University, Portland, OR, USA.
  • Wang X; Department of medical laboratory technology, Taibah University, Al-Madinah al-Munawwarah, Saudi Arabia.
  • Calistri NL; Department of Molecular and Medical Genetics, Oregon Health & Science University, Portland, OR, USA.
  • Eng J; Department of Biomedical Engineering, Oregon Health & Science University, Portland, OR, USA.
  • Daniel CJ; Department of Molecular and Medical Genetics, Oregon Health & Science University, Portland, OR, USA.
  • Ternes L; Department of Biomedical Engineering, Oregon Health & Science University, Portland, OR, USA.
  • Kim EN; OHSU Center for Spatial Systems Biomedicine, Oregon Health & Science University, Portland, OR, USA.
  • Pelz C; Department of Molecular and Medical Genetics, Oregon Health & Science University, Portland, OR, USA.
  • Munks M; Department of Biomedical Engineering, Oregon Health & Science University, Portland, OR, USA.
  • Betts C; Department of Biomedical Engineering, Oregon Health & Science University, Portland, OR, USA.
  • Kwon S; Department of Molecular and Medical Genetics, Oregon Health & Science University, Portland, OR, USA.
  • Bucher E; Brenden-Colson Center for Pancreatic Care, Oregon Health & Science University, Portland, OR, USA.
  • Li X; Brenden-Colson Center for Pancreatic Care, Oregon Health & Science University, Portland, OR, USA.
  • Waugh T; Department of Molecular Microbiology and Immunology, Oregon Health and Science University, Portland, OR, USA.
  • Tatarova Z; Department of Cell, Developmental & Cancer Biology, Oregon Health and Science University, Portland, OR, USA.
  • Blumberg D; Department of Biomedical Engineering, Oregon Health & Science University, Portland, OR, USA.
  • Ko A; OHSU Center for Spatial Systems Biomedicine, Oregon Health & Science University, Portland, OR, USA.
  • Kirchberger N; Department of Biomedical Engineering, Oregon Health & Science University, Portland, OR, USA.
  • Pietenpol JA; OHSU Center for Spatial Systems Biomedicine, Oregon Health & Science University, Portland, OR, USA.
  • Sanders ME; Division of Oncologic Sciences, Oregon Health and Science University, Portland, OR, USA.
  • Langer EM; Department of Molecular and Medical Genetics, Oregon Health & Science University, Portland, OR, USA.
  • Dai MS; Department of Biomedical Engineering, Oregon Health & Science University, Portland, OR, USA.
  • Mills G; OHSU Center for Spatial Systems Biomedicine, Oregon Health & Science University, Portland, OR, USA.
  • Chin K; Department of Biomedical Engineering, Oregon Health & Science University, Portland, OR, USA.
  • Chang YH; OHSU Center for Spatial Systems Biomedicine, Oregon Health & Science University, Portland, OR, USA.
  • Coussens LM; Department of Molecular Microbiology and Immunology, Oregon Health and Science University, Portland, OR, USA.
  • Gray JW; Department of Cell, Developmental & Cancer Biology, Oregon Health and Science University, Portland, OR, USA.
  • Heiser LM; Department of Biochemistry, Vanderbilt University Medical Center, Nashville, TN, USA.
  • Sears RC; Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, USA.
Nat Commun ; 14(1): 5665, 2023 09 13.
Article em En | MEDLINE | ID: mdl-37704631
ABSTRACT
Triple-negative breast cancer (TNBC) patients have a poor prognosis and few treatment options. Mouse models of TNBC are important for development of new therapies, however, few mouse models represent the complexity of TNBC. Here, we develop a female TNBC murine model by mimicking two common TNBC mutations with high co-occurrence amplification of the oncogene MYC and deletion of the tumor suppressor PTEN. This Myc;Ptenfl model develops heterogeneous triple-negative mammary tumors that display histological and molecular features commonly found in human TNBC. Our research involves deep molecular and spatial analyses on Myc;Ptenfl tumors including bulk and single-cell RNA-sequencing, and multiplex tissue-imaging. Through comparison with human TNBC, we demonstrate that this genetic mouse model develops mammary tumors with differential survival and therapeutic responses that closely resemble the inter- and intra-tumoral and microenvironmental heterogeneity of human TNBC, providing a pre-clinical tool for assessing the spectrum of patient TNBC biology and drug response.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Mamárias Animais / Neoplasias de Mama Triplo Negativas Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Mamárias Animais / Neoplasias de Mama Triplo Negativas Idioma: En Ano de publicação: 2023 Tipo de documento: Article